StreetInsider.com News Articles

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: GOLDBERG MARK A

Mon, 20 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260720/26789665.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: GOLDBERG MARK A

Mon, 20 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260720/26789665.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: Donovan Daniel

Mon, 20 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260720/26789667.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: Donovan Daniel

Mon, 20 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260720/26789667.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: DUBIN THOMAS I H

Mon, 20 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260720/26789670.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: DUBIN THOMAS I H

Mon, 20 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260720/26789670.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: Talamo Joseph

Mon, 20 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260720/26789649.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: Talamo Joseph

Mon, 20 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260720/26789649.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: Wesolowski John M

Mon, 20 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260720/26789656.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: Wesolowski John M

Mon, 20 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260720/26789656.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: Leahy Emer

Mon, 20 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260720/26789659.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: Leahy Emer

Mon, 20 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260720/26789659.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: BENDER LEWIS H

Mon, 20 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260720/26789630.html

Form 4 INTENSITY THERAPEUTICS, For: Jul 16 Filed by: BENDER LEWIS H

Mon, 20 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260720/26789630.html

Intensity Therapeutics resumes breast cancer trial in Switzerland

Wed, 15 Jul 2026 07:45:21 -0400

Intensity Therapeutics, Inc. (Nasdaq: INTS) announced July 15 that it has resumed patient dosing in its INVINCIBLE-4 Study, a Phase 2 clinical trial evaluating its drug candidate INT230-6 in patients with early-stage, operable triple-negative breast cancer.

The trial, identified as NCT06358573, had been paused to evaluate skin irritation observed in some patients. In March 2026, the company submitted a protocol amendment to Swissmedic and the Swiss Ethics Committee to resume enrollment using a lower drug-to-tumor volume ratio and a single injection of INT230-6. New patients have since been dosed in Switzerland.

The study uses a two-cohort design. One cohort receives a single

Intensity Therapeutics resumes breast cancer trial in Switzerland

Wed, 15 Jul 2026 07:45:21 -0400

The study uses a two-cohort design. One cohort receives a single

Intensity Therapeutics resumes breast cancer trial in Switzerland

Wed, 15 Jul 2026 07:45:21 -0400

The study uses a two-cohort design. One cohort receives a single

Intensity Therapeutics resumes breast cancer trial in Switzerland

Wed, 15 Jul 2026 07:45:21 -0400

The study uses a two-cohort design. One cohort receives a single

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

Wed, 15 Jul 2026 07:45:00 -0400